Table 2.

Participant baseline and follow-up medications by drug class (N=48).

Diabetes medication classes	Participants, n (%)
	Baseline	Baseline medication stopped	Medication addition during study	Follow-up
Alpha glucosidase inhibitor	1 (2.1)	0 (0)	0 (0)	1 (2.1)
Biguanide	40 (83.3)	0 (0)	3 (6.3)	43 (89.6)
DPP-4a inhibitor	8 (16.7)	7 (14.6)	2 (4.2)	3 (6.2)
GLP-1b receptor agonist	12 (25)	1 (2.1)	16 (33.3)	27 (56.2)
Insulin	18 (37.5)	0 (0)	2 (4.2)	20 (41.7)
SGLT2c inhibitor	18 (37.5)	2 (4.2)	3 (6.3)	19 (39.6)
Sulfonylurea	27 (56.2)	13 (27.1)	2 (4.2)	16 (33.3)
Thiazolidinedione	1 (2.1)	0 (0)	0 (0)	1 (2.1)
Other diabetes medications	0 (0)	0 (0)	4 (8.3)	4 (8.3)

^aDPP-4: dipeptidyl peptidase-4.

^bGLP-1: glucagon-like peptidase-1.

^cSGLT2: sodium/glucose cotransporter 2.